VIR Flashcards
(375 cards)
MELD
3m survival in pts post TIPS and to prioritize pts for transplant
Based on Cr, Tbili, INR
Barcelona-Clınic Liver Cancer (BCLC) staging
1) 3 components?
2) How is is scored and what is the treatment for each score?
3) Survival for each score?
1) 3 Components:
- Child Pugh - BA-PEA
- Performance status - ECOG 0 to 5
- Tumor characteristics (size, #, vascular invasion,
MPV-HV gradient)
2) Scored 0, A, B, C, D:
- 0 & A: Early: curative tx (surgery/transplant/RFA)
- B: Intermediate: multinodular tx with TACE,
- C: Advanced: vascular invasive/metastatic, tx
with Sorafenib
- D: Terminal: symptomatic tx.
3) Survival
- 0 & A: 36m
- B: 16m
- C: 6m
- D: 1m
Rx for arterial stenting
Maggie does 3 months on everyone. Longer if CLI, poor runoff, < 7 mm stent, stent graft). Procedural loading dose of 300mg or start 24h before with daily dose 75 mg qd and lifelong ASA.
EASL: European Association for the Study of the Liver
Looks at enhancement to evaluate tumor necrosis
Amplatzer sizing for arteries and veins
Arteties: 20-40% upsize
Veins: double the size of the plug.
Bronchial artery location?
N4
2L, 1R at T5-6
Just do bronchials with particles > 250u to minimize risk of tissue necrosis and decrease risk to spinal arteries.
Leaking Gtube
1) PPI 4-6w
2) Low profile to decrease torque
3) Wound care
Venous malformations embo agent
Ethanol (1 ml/kg)
Max injection rate 0.1cc/kg/5 min (vs Sotradecol which is 0.5cc/kg/5 min)
Can also use for cysts
Sotrodecol can also be used. May be more mild than alcohol when lesion superficial.
LM embo agent
Doxycycline
UAE vs. Myomectomy in pregnancy
Similar pregnancy and complication rates, but higher miscarriage rates
Endovascular treatment of BtK CTO
Start 014 hydrophilic and then increase to larger stiffer wire if unable to cross.
Once CTO crossed switch to stiffer support wire.
Tx with angioplasty or atherecromy.
Transplant criteria
3/5
4.5/6.5
Milan: transplant eligible if single tumor < 5 cm or up to 3, each smaller than 3 cm.
UCSF: transplant eligible if single tumor < 6.5 cm or up to 3, each smaller than 4.5 cm - with total diameter not exceeding 8 cm.
Requirements for surgical rsxn in HCC pts? - only 10% pt eligible!
ECOG?
CP?
Lesion size?
PVHV Gradient?
- ECOG 0
- Child Pugh A
- Single lesion < 2 cm
- PVHV gradient < 10
RFA of HCC results most favorable with tumor size less than….?
3 cm
Note, for lesions < 2 cm, outcomes similar to surgery.
Heat sink in RFA and cold sink in cryo most likely to occur when tumor abuts vessel of what size?
> 3 mm
TACE survival benefit?
Two landmark prospective randomized trials demonstrated IMPROVED OVERALL SURVIVAL FOR TACE COMPARED WITH BEST SUPPORTIVE CARE in patients with HCC and preserved liver function (level IA evidence).
Lo: patients treated with TACE had 1-, 2-, and 3-year survival rates of 57%, 31%, and 26%, respectively, compared with 32%, 11%, and 3% in controls.
Llovet: trial stopped early when sequential inspection demonstrated that TACE had a significantly improved survival compared with conservative tx. One and 2-year survival rates for chemoembolization were 75% and 50%, respectively, compared with 63% and 27% for the control group.
When is TACE considered first line?
- Intermediate stage (BCLC B) dz - large or multi nodular HCC with:
a) relatively preserved liver function (Child Pugh A & B),
b) absence of cancer related symptoms (ECOG 0),
c) no evidence of vascular invasion or extrahepatic spread.
Criteria: Severe limb ischemia
1) rest pain
2) ulceration
3) gangrene
VIBRANT Trial
VIABAHN endograft vs. BMS in tx of complex SFA dz.
No difference in patency rates noted. However, graft was the old Viabhan. Now, there is heparin bonding and contoured edges.
Primary patency
Exempt from restenosis of the target lesion during follow-up.
NO RESTENOSIS
Primary assisted patency
Patency of the target lesion following endovascular reintervention at the site of a symptomatic restenosis.
PATENCY OF SYMPTOMATIC RESTENOSIS AFTER INTERVENTION
Situation whereby patency is never lost but is maintained by prophylactic intervention
Secondary patency
Patency of the target lesion after treatment of a (re)occlusion of the index lesion.
Covered vs uncovered biliary stents?
Krokidis: Bard eLuminexx BMS vs. Gore Viabil for palliation of malignant jaundice caused by pancreatic head masses (adeno/cholangio).
Covered stents do not afford survival benefit but demonstrate superior primary patency rates, decreased tumor in-growth, improved pt QOL and requires fewer re-interventions.
VIASTAR Trial
Heparin-bonded covered stents (Viabhahn) vs. sE BMS in long fem pop lesions ≥20 cm.
Heparin bonded stent grafts demonstrated significant clinical and patency benefits.
This was update to VIBRANT trial.